rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MLTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Moonlake stock price target maintained at $34 by Wedbush
      Nov 12Investing.comMLTX
      MoonLake Immunotherapeutics (MLTX) Stock Could Be Above Fair Value On Book Value Concerns

      MoonLake Immunotherapeutics has seen sharp swings over the past few years, and the latest share price level puts fresh focus on a simple question for you as an investor: Is the current valuation of MoonLake Immunotherapeutics stock meaningfully backed up by the strength of its balance sheet and its book value per share? Over the last 3 years the share price has fallen 66.5%, which puts a lot of weight on whether the current market value still lines up with the underlying net assets on the...

      Nov 12Yahoo FinanceMLTX
      Is MoonLake Immunotherapeutics (MLTX) Cheap On Earnings Losses And Sonelokimab Milestones?

      MoonLake Immunotherapeutics (MLTX) just posted third quarter 2026 results, reporting a net loss of US$79.55 million and a diluted loss per share of US$0.93. The company also reaffirmed its focus on sonelokimab regulatory milestones. The latest earnings update landed after a sharp pullback, with MoonLake Immunotherapeutics now trading at US$12.56. The 7 day share price return of 7.35% and 30 day gain of 16.08% suggest short term momentum is rebuilding, even though the 90 day share price return...

      Nov 11Yahoo FinanceMLTX
      MoonLake Immunotherapeutics Stock In Focus After Quarterly Loss Update
      Nov 10Yahoo FinanceMLTX
      Chardan initiates Moonlake stock with buy rating on HS drug outlook
      Nov 6Investing.comMLTX
      MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
      Nov 4Yahoo FinanceMLTX
      MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds
      Oct 25Yahoo FinanceMLTX
      MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions
      Oct 25Yahoo FinanceMLTX
      What's Going On with MoonLake Immunotherapeutics Stock on Thursday?
      Oct 22BenzingaMLTX
      MoonLake: Downgrading To Hold As FDA Priority Review Decision Remains (NASDAQ:MLTX)

      MoonLake Immunotherapeutics BLA filing for sonelokimab in HS, VELA phase 3 HiSCR75 data, and PsA IZAR-1 readouts—click to see what’s next for MLTX investors.

      Oct 20Seeking AlphaMLTX
      MoonLake’s sonelokimab faces regulatory, commercial tests, RBC says (MLTX:NASDAQ)
      Oct 18Seeking AlphaMLTX
      MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says
      Oct 16Yahoo FinanceMLTX
      MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says

      MoonLake Immunotherapeutics (MLTX) could receive US Food and Drug Administration approval for sonelo

      Oct 5Yahoo FinanceMLTX
      MoonLake Immunotherapeutics (MLTX) Receives a Rating Update from a Top Analyst

      Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailMLTX
      Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), United Therapeutics (UTHR) and NervGen Pharma (NGEN)

      Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailMLTX
      Cantor Fitzgerald reiterates Moonlake stock rating at Overweight
      Sep 16Investing.comMLTX
      MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
      Sep 8Seeking AlphaMLTX
      MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

      ZUG, Switzerland, August 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive...

      Aug 31BarchartMLTX

      This is the newest page. Registered accounts read further back.